NIH has launched a human trial for LASSARAB, a dual-purpose vaccine targeting Lassa fever and rabies. Early animal studies ...

The NIH announced the beginning of a phase 1 first-in-human trial of a vaccine for Lassa fever, a potentially fatal viral hemorrhagic disease for which there is no approved vaccine or treatment.

NIH-Sponsored Trial of Lassa Vaccine Opens - Viral Hemorrhagic Disease Can be Fatal & Causes Permanent Hearing Loss ...

Lassa fever vaccine is one step closer to approval. Lassa virus infections, primarily spread by rodents, can cause a fatal ...

The NCDC on Wednesday, confirmed 563 Lassa fever cases out of the 2,960 suspected cases of the disease and 103 deaths as of ...

Since September 2024, PhilHealth has introduced 13 new and enhanced benefit packages, including a 144 percent increase in ...

An NIH-sponsored clinical trial of a candidate vaccine to prevent Lassa fever has begun enrolling participants.

The situation report of the hemorrhagic fever for Week 10 also showed that the disease has spread to 14 states and 78 local government areas with a Case Fatality Ratio of 18.3 per cent.

A renowned virologist and former vice-chancellor of Redeemer’s University, Prof. Oyewale Tomori, has warned that Lassa fever ...

Renowned Nigerian physician, Dr. Tochi Okwor, said that the 2018 Lassa fever outbreak exposed critical gaps in the nation’s infection ...

The Philippine Health Insurance Corporation or PhilHealth paid for pneumonia, stroke and infarction, pneumonia (high-risk), ...

The country is presently battling its eighth Ebola outbreak, confirmed by the Ministry of Health in January, with two ...